187 related articles for article (PubMed ID: 23754221)
1. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
Cambon K; Déglon N
Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
Vachey G; Déglon N
Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
[TBL] [Abstract][Full Text] [Related]
3. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
4. Viral-mediated overexpression of mutant huntingtin to model HD in various species.
Ruiz M; Déglon N
Neurobiol Dis; 2012 Nov; 48(2):202-11. PubMed ID: 21889981
[TBL] [Abstract][Full Text] [Related]
5. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
7. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
[TBL] [Abstract][Full Text] [Related]
8. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells.
Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N
PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995
[TBL] [Abstract][Full Text] [Related]
9. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
[TBL] [Abstract][Full Text] [Related]
12. RNAi silencing in mouse models of neurodegenerative diseases.
Farah MH
Curr Drug Deliv; 2007 Apr; 4(2):161-7. PubMed ID: 17456035
[TBL] [Abstract][Full Text] [Related]
13. Applications of lentiviral vectors for biology and gene therapy of neurological disorders.
Lundberg C; Björklund T; Carlsson T; Jakobsson J; Hantraye P; Déglon N; Kirik D
Curr Gene Ther; 2008 Dec; 8(6):461-73. PubMed ID: 19075629
[TBL] [Abstract][Full Text] [Related]
14. RNAi-based therapies for Huntington's disease: delivery challenges and opportunities.
Mantha N; Das SK; Das NG
Ther Deliv; 2012 Sep; 3(9):1061-76. PubMed ID: 23035592
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral-mediated delivery of siRNAs for antiviral therapy.
Morris KV; Rossi JJ
Gene Ther; 2006 Mar; 13(6):553-8. PubMed ID: 16397511
[TBL] [Abstract][Full Text] [Related]
16. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C
Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington's Disease.
Young D
Methods Mol Biol; 2016; 1382():383-95. PubMed ID: 26611601
[TBL] [Abstract][Full Text] [Related]
18. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.
Aronin N; DiFiglia M
Mov Disord; 2014 Sep; 29(11):1455-61. PubMed ID: 25164989
[TBL] [Abstract][Full Text] [Related]
19. Genetic modifiers of Huntington's disease.
Gusella JF; MacDonald ME; Lee JM
Mov Disord; 2014 Sep; 29(11):1359-65. PubMed ID: 25154728
[TBL] [Abstract][Full Text] [Related]
20. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model.
Mendonça MCP; Cronin MF; Cryan JF; O'Driscoll CM
Eur J Pharm Biopharm; 2021 Dec; 169():309-318. PubMed ID: 34793942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
